Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 7;12(2):e11223.
doi: 10.15252/emmm.201911223. Epub 2020 Jan 8.

Safe Eradication of Large Established Tumors Using Neovasculature-Targeted Tumor Necrosis Factor-Based Therapies

Free article

Safe Eradication of Large Established Tumors Using Neovasculature-Targeted Tumor Necrosis Factor-Based Therapies

Leander Huyghe et al. EMBO Mol Med. .
Free article


Systemic toxicities have severely limited the clinical application of tumor necrosis factor (TNF) as an anticancer agent. Activity-on-Target cytokines (AcTakines) are a novel class of immunocytokines with improved therapeutic index. A TNF-based AcTakine targeted to CD13 enables selective activation of the tumor neovasculature without any detectable toxicity in vivo. Upregulation of adhesion markers supports enhanced T-cell infiltration leading to control or elimination of solid tumors by, respectively, CAR T cells or a combination therapy with CD8-targeted type I interferon AcTakine. Co-treatment with a CD13-targeted type II interferon AcTakine leads to very rapid destruction of the tumor neovasculature and complete regression of large, established tumors. As no tumor markers are needed, safe and efficacious elimination of a broad range of tumor types becomes feasible.

Keywords: cancer; interferons; neovasculature; targeted therapy; tumor necrosis factor.

Similar articles

See all similar articles

Cited by 3 articles


    1. Ameloot P, Takahashi N, Everaerdt B, Hostens J, Eugster HP, Fiers W, Brouckaert P (2002) Bioavailability of recombinant tumor necrosis factor determines its lethality in mice. Eur J Immunol 32: 2759-2765
    1. Betz UA, Vosshenrich CA, Rajewsky K, Muller W (1996) Bypass of lethality with mosaic mice generated by Cre-loxP-mediated recombination. Curr Biol 6: 1307-1316
    1. Boone E, Vanden Berghe T, Van Loo G, De Wilde G, De Wael N, Vercammen D, Fiers W, Haegeman G, Vandenabeele P (2000) Structure/Function analysis of p55 tumor necrosis factor receptor and fas-associated death domain. Effect on necrosis in L929sA cells. J Biol Chem 275: 37596-37603
    1. Brouckaert PG, Leroux-Roels GG, Guisez Y, Tavernier J, Fiers W (1986) In vivo anti-tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN-gamma, on a syngeneic murine melanoma. Int J Cancer 38: 763-769
    1. Cauwels A, Van Lint S, Garcin G, Bultinck J, Paul F, Gerlo S, Van der Heyden J, Bordat Y, Catteeuw D, De Cauwer L et al (2018a) A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment. Oncoimmunology 7: e1398876

LinkOut - more resources